NCT01376258View on ClinicalTrials.gov

Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database

CompletedOBSERVATIONAL

Enrollment

28,903

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Prostatic Hyperplasia

Interventions

DRUG

5ARI

dutasteride or finasteride

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01376258 - Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database | Biotech Hunter | Biotech Hunter